MesoTV Podcast: Conversations Impacting the Mesothelioma Community

MesoTV: The surgical approach to meso and how genetics impact treatment

We sit down for a conversation with Raphael Bueno, MD, of Harvard Medical School and Brigham and Women’s Hospital in Boston, MA to discuss the surgical approach to mesothelioma and how genetics impact treatment.

Radiation and immunotherapy: emerging mechanisms of synergy w/ Dr. Breen from Mayo Clinic

Dr. William Breen of the Mayo Clinic joins us in a conversation about Dr. Breen's study exploring synergy processes between radiation therapy in combination with immunotherapy.

Chemotherapy + immunotherapy, another positive step in mesothelioma treatment

NOW ENROLLING: Immunotherapy + chemotherapy as first line treatment for mesothelioma Drs. Anne Tsao of MD Anderson Cancer Center, Patrick Forde of Johns Hopkins, and James Stevenson of the Cleveland Clinic join Mary Hesdorffer to discuss a new clinical trial, Dream3r, a phase 3 study into the efficacy of combination chemotherapy with immunotherapy as first line treatment for mesothelioma.

”Does staging matter in mesothelioma” with Dr. James Stevenson of the Cleveland Clinic

Discussion with Dr. James Stevenson of the Cleveland Clinic about staging of mesothelioma. Does staging matter and can it predict outcomes? Cancer staging conveys to the patient and physician information about the cancer's spread (for example, has the the cancer metastasized to the lymphatic system or other organs, etc.) This information is used to determine the course of treatment (i.e. whether the cancer is operable or not), as well as prognosis (predicting a patient’s survival time). For scientists, this classification is also helpful in a research setting as it allows comparison of patients (simplistically, it allows them to compare apples to apples.) Currently, staging for pleural mesothelioma (peritoneal mesothelioma does not have a standardized staging system) is based on the TNM system. T: the extent of spread of the main tumor. N: the spread of cancer to nearby (regional) lymph nodes. M: indicates whether the cancer has spread (metastasized) to other organs of the body.

Pneumonitis in immunotherapy-treated mesothelioma patients

Pneumonitis is a serious treatment-related side effect of both radiation, immunotherapy and some chemotherapies. This episode of MesoTV includes discussion on diagnosis, treatment and the dilemma facing both patients and doctors while making decisions on how to approach mesothelioma specific therapy during and post treatment for this condition. Dr. Daniel Sterman is a member of the Board of Directors at the Mesothelioma Applied Research Foundation. He is also Director of Pulmonary, Critical Care and Sleep Medicine at NYU Langone Medical Center. More information about MesoTV is available at www.curemeso.org/mesotv. More information about the Mesothelioma Applied Research Foundation can be found at www.curemeso.org.

Peritoneal mesothelioma surgery and treatment at the National Cancer Institute

Dr. Andrew Blakely, MD, of the National Cancer Institute joins us to discuss peritoneal mesothelioma surgery and treatment. Dr. Blakely is a surgical oncologist specializing in peritoneal surface malignancies and soft tissue sarcomas. More information about MesoTV is available at www.curemeso.org/mesotv. More information about the Mesothelioma Applied Research Foundation can be found at www.curemeso.org.

Toxicities, side-effects, from immunotherapy for treatment of mesothelioma

Dr. Jarushka Naidoo of Beaumont Hospital Dublin and Johns Hopkins, and Michelle Turner, NP, of Johns Hopkins join moderator Mary Hesdorffer to discuss side-effects of immunotherapy. If you found this video helpful, please Like and Subscribe to make sure others can find it as well. For more videos like this one, visit www.curemeso.org/mesotv

CLINICAL TRIAL: Engineered T-cell therapy (TC-210, gavo-cel) for mesothelioma

Dr. Melissa Johnson of the Sarah Cannon Cancer Center in Nashville, TN talks to us about a multi-center clinical trial utilizing engineered t-cell therapy similar to CAR-T but better known as TRuC-T therapy (stands for TCR Fusion Construct T cells). While CAR-T cell therapy engineers the patient's own T-cells with chimeric antigen receptors (CARs), Truc-t therapy engineers T-cell receptors (TCRs). Dr. Johnson is a thoracic medical oncologist and is the program director of Lung Cancer Research at Sarah Cannon Cancer Center. Learn more about MesoTV at www.curemeso.org/mesotv.

CLINICAL TRIAL: Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

CLINICAL TRIAL: Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Overview of new clinical trial for patients with resectable pleural mesothelioma looking into benefits of immunotherapy treatment prior to surgery. The trial compares two arms: in one arm patients are treated with nivolumab only prior to surgery; in the other arm they are treated with nivolumab + ipilimumab. This interview is moderated by Buerkley Rose, MSN, RN of the University of Chicago Medicine, and features the principal investigator of the study, Patrick Forde, MD of Johns Hopkins. The interview also provides insight from two surgeons participating in the trial: Joseph Friedberg, MD of the University of Maryland Medical Center, and Richard Battafarano, MD, PhD of Johns Hopkins.

More information about MesoTV is available at www.curemeso.org/mesotv. More information about the Mesothelioma Applied Research Foundation can be found at www.curemeso.org.

Current trends in mesothelioma treatment - discussion by thought-leaders in this disease

A conversation with Dr. Hedy Kindler of the University of Chicago Medicine, and Dr. Sanjay Popat of the Royal Marsden in the UK, about current trends and advances in mesothelioma treatment with a special focus on immunotherapy, chemotherapy, and various combinations thereof. Moderated by Dr. Marjorie G. Zauderer of Memorial Sloan Kettering Cancer Center and chair of the board of directors of the Mesothelioma Applied Research Foundation.

More information about MesoTV is available at www.curemeso.org/mesotv. More information about the Mesothelioma Applied Research Foundation can be found at www.curemeso.org.